Cargando…

Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression

OBJECTIVES: Murine models of interleukin (IL)-23-driven spondyloarthritis (SpA) have demonstrated entheseal accumulation of γδT-cells which were responsible for the majority of local IL-17A production. However, IL-23 blockers are ineffective in axial inflammation in man. This study investigated γδT-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuthbert, Richard James, Watad, Abdulla, Fragkakis, Evangelos M, Dunsmuir, Robert, Loughenbury, Peter, Khan, Almas, Millner, Peter A, Davison, Adam, Marzo-Ortega, Helena, Newton, Darren, Bridgewood, Charlie, McGonagle, Dennis G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837256/ https://www.ncbi.nlm.nih.gov/pubmed/31530557 http://dx.doi.org/10.1136/annrheumdis-2019-215210

Ejemplares similares

Identification of myeloid cells in the human enthesis as the main source of local IL-23 production
por: Bridgewood, Charlie, et al.
Publicado: (2019)

IL-17A and TNF Modulate Normal Human Spinal Entheseal Bone and Soft Tissue Mesenchymal Stem Cell Osteogenesis, Adipogenesis, and Stromal Function
por: Russell, Tobias, et al.
Publicado: (2021)

Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression
por: Watad, Abdulla, et al.
Publicado: (2020)

Characterization of Blood Mucosal‐Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal‐Associated Invariant T Cells From the Axial Entheses of Non‐Axial Spondyloarthritis Control Patients
por: Rosine, Nicolas, et al.
Publicado: (2022)

The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man
por: Bridgewood, Charlie, et al.
Publicado: (2019)

Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis
por: McGonagle, Dennis, et al.
Publicado: (2021)

SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights
por: Zhou, Qiao, et al.
Publicado: (2021)

Intestinal and enthesis innate immunity in early axial spondyloarthropathy
por: Sharif, Kassem, et al.
Publicado: (2020)

Corrigendum to: Intestinal and enthesis innate immunity in early axial spondyloarthropathy
por: Sharif, Kassem, et al.
Publicado: (2020)

Cytokine “fine tuning” of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies
por: Russell, Tobias, et al.
Publicado: (2021)

Enthesitis: Much More Than Focal Insertion Point Inflammation
por: Watad, Abdulla, et al.
Publicado: (2018)

The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science
por: Watad, Abdulla, et al.
Publicado: (2018)

New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function
por: Saviano, Anella, et al.
Publicado: (2023)

Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply
por: McGonagle, Dennis, et al.
Publicado: (2022)

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells
por: Shah, Mittal, et al.
Publicado: (2020)

Sex-Based Medicine Meets Psoriatic Arthritis: Lessons Learned and to Learn
por: Bragazzi, Nicola Luigi, et al.
Publicado: (2022)

MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?
por: Toussirot, Eric, et al.
Publicado: (2018)

Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection
por: McGonagle, Dennis, et al.
Publicado: (2020)

Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats
por: Hayashi, Hiroki, et al.
Publicado: (2023)

The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier
por: Macleod, Tom, et al.
Publicado: (2021)

COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics – Author's reply
por: McGonagle, Dennis, et al.
Publicado: (2021)

COVID-19 vasculitis and novel vasculitis mimics
por: McGonagle, Dennis, et al.
Publicado: (2021)

Harnessing Big Data, Smart and Digital Technologies and Artificial Intelligence for Preventing, Early Intercepting, Managing, and Treating Psoriatic Arthritis: Insights From a Systematic Review of the Literature
por: Bragazzi, Nicola Luigi, et al.
Publicado: (2022)

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
por: Wei, James Cheng-Chung, et al.
Publicado: (2021)

Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
por: Michelena, Xabier, et al.
Publicado: (2022)

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
por: Marzo-Ortega, Helena, et al.
Publicado: (2017)

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
por: Marzo‐Ortega, H., et al.
Publicado: (2017)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
por: Kiltz, Uta, et al.
Publicado: (2020)

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages
por: Kiltz, U, et al.
Publicado: (2016)

Salmonella exploits HLA-B27 and host unfolded protein responses to promote intracellular replication
por: Antoniou, Antony Nicodemus, et al.
Publicado: (2019)

Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter
por: Li, Zhixiu, et al.
Publicado: (2022)

Recurrence of axial spondyloarthritis among first-degree relatives in a prospective 35-year-follow-up family study
por: van der Linden, Sjef M, et al.
Publicado: (2022)

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
por: Li, Zhixiu, et al.
Publicado: (2021)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Therapeutic implications of ongoing alveolar viral replication in COVID-19
por: McGonagle, Dennis, et al.
Publicado: (2022)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Immune cartography of macrophage activation syndrome in the COVID-19 era
por: McGonagle, Dennis, et al.
Publicado: (2021)

Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply
por: McGonagle, Dennis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eurqg5ce9rlrbkerv7se4fu85l